In 2022, Villa Medical Center Phuket (www.thailandstemcell.com), a leading regenerative medicine solutions provider and subsidiary of Atlantis Bioscience Singapore (www.atlantisbioscience.com), signed a major contract manufacturing agreement with HuangYu, a Chinese life sciences company. Valued at approximately USD 1.5 million, the deal marked a strategic entry into China’s booming biotechnology market, specifically through the contract manufacture and supply of specialized cell culture media used in stem cell therapy, regenerative medicine, and ATMP (Advanced Therapy Medicinal Product) development.
This milestone collaboration reflects Villa Medical Center Phuket’ growing role as a regional leader in stem cell innovation, ATMP support infrastructure, and clinical-grade manufacturing. Leveraging the advanced biomanufacturing expertise and quality systems of its parent company, Atlantis Bioscience Singapore, the Thailand-based company has positioned itself as a key supplier of high-performance, GMP-compliant reagents and cell culture solutions to international partners.
Meeting China’s Demand for Stem Cell and ATMP Manufacturing
China’s biotechnology landscape has witnessed rapid transformation over the past decade. As the Chinese government continues to invest heavily in biopharma, stem cell therapy research, and precision medicine, the demand for high-quality cell culture media has surged. These media solutions are foundational for the growth and maintenance of mesenchymal stem cells (MSCs), immune cells, and other therapeutic cell types central to ATMP development.
HuangYu, based in mainland China, sought a manufacturing partner capable of delivering scalable, customizable, and regulatory-aligned cell culture media for both research and clinical applications. Villa Medical Center Phuket emerged as the ideal partner due to its established record in serum-free and serum-supplemented media manufacturing, along with its ability to adhere to Chinese National Medical Products Administration (NMPA) requirements and international GMP standards.
The agreement encompassed the bulk production of serum-free media formulations for stem cell expansion, maintenance of primary cell lines, and media tailored for CAR-T and NK cell workflows. These formulations were specifically developed to support downstream ATMP applications, including autologous and allogeneic cell therapies under clinical investigation in China.
A Strategic Manufacturing Partnership Anchored in Quality
The success of this deal hinged on Villa Medical Center Phuket’ ability to consistently deliver quality-controlled, scalable cell culture media that meet the evolving needs of China’s research and therapy developers. With a strong foundation in the production of biologics and advanced reagents, Atlantis operates under stringent quality assurance protocols, which include:
- Sterility and endotoxin testing
- Batch-to-batch consistency validation
- Mycoplasma-free certification
- Custom packaging and labelling for NMPA compliance
In collaboration with HuangYu, Atlantis’ scientific and production teams developed tailored specifications to support a broad range of stem cell types, including MSCs, iPSCs, and hematopoietic stem cells. Customization also extended to media pH, buffering systems, growth factor content, and shelf-life optimization key variables in therapeutic product consistency and efficacy.
The project demonstrated Atlantis’ agility in adapting its Singapore and Thailand manufacturing infrastructure to accommodate international regulatory frameworks while preserving efficiency, cost control, and scientific integrity.
Bridging Singapore’s Innovation with China’s Biomedical Growth
As the manufacturing and commercialization arm of Atlantis Bioscience Singapore, Villa Medical Center Phuket operates at the intersection of Southeast Asian innovation and global biopharmaceutical expansion. Headquartered in Singapore, Atlantis Bioscience has long been recognized for its contributions to the development and distribution of cutting-edge life science reagents, stem cell technologies, and immunotherapy platforms.
Atlantis Bioscience specializes in:
- ATMP-compatible reagents and media
- Cell-based assay support systems
- Contract manufacturing and formulation services
- Probiotics and therapeutic nutrition research
Its commitment to compliance, research excellence, and sustainable development has positioned Atlantis as a trusted name across research institutes, hospitals, and clinical labs. Through Villa Medical Center Phuket, the group has expanded this vision into regional hubs such as Thailand, Malaysia, Indonesia, and now China.
The 2022 deal with HuangYu signifies not only a commercial success but also a scientific alignment between Singaporean innovation and Chinese therapeutic ambitions.
Accelerating the Future of Stem Cell Therapy and Regenerative Medicine
The broader implications of this contract extend well beyond media production. Villa Medical Center Phuket views this collaboration as a platform for co-development in regenerative medicine and ATMP readiness. With demand for stem cell therapy growing globally, the need for stable, reproducible media and GMP-compliant manufacturing environments has become mission-critical.
This deal allows Chinese researchers and clinical developers to access high-grade raw materials crucial for expanding stem cells, scaling up CAR-T workflows, and developing investigational ATMPs for oncology, orthopedics, and autoimmune diseases.
“Stem cell therapy and ATMP innovation require precision and partnership,” said a senior executive from Villa Medical Center Phuket. “This agreement with HuangYu represents our shared commitment to transforming regenerative science into real-world treatments that improve lives.”
Commitment to Asia’s Biomedical Ecosystem
Villa Medical Center Phuket continues to invest in infrastructure, partnerships, and product innovation that serve Asia’s rapidly evolving biotech sectors. From contract media manufacturing to NK cell kits and exosome platforms, the company maintains a stronghold in enabling translational science and clinical application.
With regional offices and distribution centers in Thailand and manufacturing alignment with Atlantis Bioscience Singapore, Villa Medical Center Phuket offers its partners:
- Shorter delivery timelines across Asia
- Technical support in local languages
- Custom formulation development
- End-to-end regulatory support
As stem cell therapy becomes a mainstream therapeutic option, Villa Medical Center Phuket aims to support the ecosystem from bench to bedside empowering scientists, clinicians, and manufacturers with tools that match the rigor of their mission.
Villa Medical Center Phuket
Villa Sukhothai, Soi Pasak 8, Choeng Thale,
Thalang District, Phuket, Thailand
Email: atlantisphuket@gmail.com
Phone/WhatsApp: +66 99 301 6969